Category: quinoxaline

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.879-65-2,2-Quinoxalinecarboxylic acid,as a common compound, the synthetic route is as follows.,879-65-2

Preparation of Quinoxaline-2-carboxylic acid {(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide Following the general procedure of Examples 280h-j except substituting quinoxaline-2-carboxylic acid for benzofuran-2-carboxylic acid and 1-propanesulfonyl chloride for 3-flurobenzenesulfonyl chloride provided the title compound as a mixture of diastereomers. Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 503.4 (M+H)+and diastereomer 2 MS(ES) 503.4 (M+H)+.

879-65-2 2-Quinoxalinecarboxylic acid 96695, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; SmithKline Beecham Corporation; US2002/147188; (2002); A1;; ; Patent; SmithKline Beecham Corporation; US2003/144175; (2003); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

1204-75-7, 3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

The resulting compound (2.00 g, 6.84 mmol) was condensed with 3-hydroxyquinoxaline-2-carboxylic acid (1.48 g, 7.80 mmol) under nitrogen stream to afford the desired title compound (2.71 g, yield 85%) as a pale yellow solid. 1H-NMR (DMSO-d6, 400 MHz) delta: 12.88 (1H, s), 9.62 (1H, d, J=6.0 Hz), 7.87 (1H, dd, J=7.6 Hz, 2.0 Hz), 7.65 (1H, dt, J=7.6 Hz, 2.0 Hz), 7.40 (1H, dt, J=7.6 Hz, 2.0 Hz), 7.37 (1H, d, J=7.6 Hz), 7.12 (2H, m), 7.02 (2H, m), 4.76 (1H, q, J=8.4 Hz), 4.61 (1H, m), 4.12-3.80 (2H, m), 3.60-3.20 (2H, m), 2.08-1.88 (2H, m), 1.75-1.45 (2H, m), 1.23 (1H, dd, J=6.4 Hz), 0.53-0.38 (4H, m). MS (ESI, m/z): 465 (M+H)+. Anal. Calcd for C25H25FN4O4: C, 64.64; H, 5.42; N, 12.06. Found: C, 64.27; H, 5.30; N, 12.01.

1204-75-7, 1204-75-7 3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid 71001, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; Daiichi Sankyo Company, Limited; EP2258697; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.49679-45-0,Ethyl 3-chloroquinoxaline-2-carboxylate,as a common compound, the synthetic route is as follows.

EXAMPLE 5 (Process B) Preparation of ethyl 3-(4,6-dimethoxypyrimidin-2-yloxy)quinoxaline-2-carboxylate (Compound No. 762) 100 ml of N,N-dimethylformamide was added to 2.3 g (9.72 mmol) of ethyl 3-chloroquinoxaline-2-carboxylate, 2.0 g (12.8 mmol) of 4,6-dimethoxy-2-hydroxypyrimidine and 1.8 g (13.0 mmol) of potassium carbonate, and the mixture was heated and stirred at 100 C. for 23 hours. After cooling, the reaction solution was poured into water, extracted with ethyl acetate, washed with water and a saturated sodium chloride aqueous solution, and then dried over anhydrous sodium sulfate. Then, the solvent was distilled off under reduced pressure, and the residue was purified by column chromatography to obtain 2.2 g (yield: 64.7%) of the desired product. Refractive index: 1.5933.

49679-45-0, 49679-45-0 Ethyl 3-chloroquinoxaline-2-carboxylate 12283436, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; Kumiai Chemical Industry Co., Ltd.; Ihara Chemical Industry Co., Ltd.; US5527763; (1996); A;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

887590-25-2, tert-Butyl 3,4-dihydroquinoxaline-1(2H)-carboxylate is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 6; 1-Butyl-4-[(3-(pyridin-3-yl)pyrrolidin-1-yl)carbonyl]-1,2,3,4-tetrahydroquinoxaline Hydrochloride (Compound No. 119); 6.1: tert-Butyl 4-[(3-(pyridin-3-yl)pyrrolidin-1-yl)carbonyl]-3,4-dihydroquinoxaline-1(2H)-carboxylate; 2.75 g of the tert-butyl ester of 3,4-dihydro-1(2H)-quinoxalinecarbamic acid, 117 ml of dichloromethane and 5.8 ml of diisopropylethylamine are placed in a 500 ml round-bottomed flask under a nitrogen atmosphere. 1.74 g of triphosgene are added at 0 C. and then the reaction mixture is left stirring at ambient temperature for three hours. 2 ml of diisopropylethylamine and 1.83 g of 3-(pyrrolidin-3-yl)pyridine are subsequently added and the reaction mixture is stirred for eighteen hours. 200 ml of a saturated aqueous sodium hydrogencarbonate solution are added and then the aqueous phase is extracted three times with dichloromethane. The organic phases are combined and dried over sodium sulfate and the solvent is evaporated under reduced pressure. The residue is chromatographed on silica gel with a dichloromethane/methanol 95/5 mixture. 3.72 g of tert-butyl 4-[(3-(pyridin-3-yl)pyrrolidin-1-yl)carbonyl]-3,4-dihydroquinoxaline-1(2H)-carboxylate are obtained.M+H+=409.3, 887590-25-2

As the paragraph descriping shows that 887590-25-2 is playing an increasingly important role.

Reference£º
Patent; SANOFI-AVENTIS; US2009/176775; (2009); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1204-75-7,3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid,as a common compound, the synthetic route is as follows.

1204-75-7, The resulting compound (317 mg, 1.00 mmol) was condensed with 3-hydroxyquinoxaline-2-carboxylic acid (190 mg, 1.00 mmol) to afford the desired title compound (358 mg, yield 79%) as a pale yellow solid. 1H-NMR (DMSO-d6, 400 MHz) delta: 12.86 (1H, brs), 9.56 (1H, m), 7.88 (1H, dd, J=7.8 Hz, 7.8 Hz), 7.65 (1H, dd, J=7.8 Hz, 7.8 Hz), 7.40 (1H, d, J=7.8 Hz), 7.38 (1H, d, J=7.8 Hz), 7.14 (2H, m), 7.03 (2H, m), 5.00 (1H, m), 4.60 (1H, m), 4.03-3.79 (2H, m), 3.57-3.20 (2H, m), 2.07-1.44 (6H, m), 0.92 (3H, t, J=7.4 Hz). IR (KBr) cm-1: 2965, 1690, 1630, 1505, 1205. MS (ESI, m/z): 453 (M+H)+. HRMS (ESI, m/z): 453.1950 (Calcd for C24H26FN4O4: 453.1938) Anal. Calcd for C24H25FN4O4: C, 63.71; H, 5.57; N, 12.38; F, 4.20. Found: C, 63.67; H, 5.46; N, 12.42; F, 4.09.

1204-75-7 3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid 71001, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; Daiichi Sankyo Company, Limited; EP2258697; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

6924-66-9, Quinoxaline-5-carboxylic acid is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

6924-66-9, PyBOP (153 mg, 295 mumol) was added to a mixture of 8-amino-2-(4-fluorophenyl)-2- azaspiro[4.5]decan-1 -one (isomer 1 , Intermediate 118) (64.4 mg, 246 muiotaetaomicronIota), quinoxaline-5- carboxylic acid (56.3 mg, 307 muiotaetaomicronl) and N,N-diisopropylethylamine (210 mul, 1 .2 mmol) in DMF (1 .0 ml) and the mixture was stirred over night at room temperature. For work-up, water was added and the mixture was extracted with dichloromethane. The organic phase was washed with water, filtered through a silicone filter and concentrated to give the title compound 93.0 mg (89 % yield).LC-MS (Method 1 ): Rt= 1 .12 min; MS (ESIneg): m/z = 417 [M-H]-1H-NMR (400 MHz, DMSO-d6): delta [ppm] = 9.77 (d, 1 H), 9.09-9.05 (m, 2H), 8.43 (dd, 1 H), 8.26 (dd, 1 H), 7.97 (dd, 1 H), 7.75-7.68 (m, 2H), 7.26-7.19 (m, 2H), 3.96-3.84 (m, 1 H), 3.79 (t, 2H), 2.12-1 .99 (m, 4H), 1.75-1 .60 (m, 4H), 1 .59-1 .45 (m, 2H)

As the paragraph descriping shows that 6924-66-9 is playing an increasingly important role.

Reference£º
Patent; BAYER PHARMA AKTIENGESELLSCHAFT; BUCHGRABER, Philipp; EIS, Knut; WAGNER, Sarah; SUeLZLE, Detlev; VON NUSSBAUM, Franz; BENDER, Eckhard; LI, Volkhart, Min-Jian; LIU, Ningshu; SIEGEL, Franziska; LIENAU, Philipp; (248 pag.)WO2018/78005; (2018); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1593-08-4,2-Formylquinoxaline,as a common compound, the synthetic route is as follows.

General procedure: A mixture of compound 2 (0.0549 g, 0.0003 mol), the appropriate aromatic aldehyde (0.00033 mol) and glacial acetic acid (0.1 mL) in ethanol (5 mL) was heated under microwave (20 W) at 80 C for 10 min. On cooling, the precipitated solid was collected by filtration, washed with water, dried and crystallized to give compounds 3-29., 1593-08-4

1593-08-4 2-Formylquinoxaline 594088, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Article; Gabr, Moustafa T.; El-Gohary, Nadia S.; El-Bendary, Eman R.; El-Kerdawy, Mohamed M.; Ni, Nanting; Chinese Chemical Letters; vol. 27; 3; (2016); p. 380 – 386;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.108229-82-9,6-Bromo-2,3-dichloroquinoxaline,as a common compound, the synthetic route is as follows.

General procedure: Method A: To a solution of compound 1 (2.78g, 0.01 mol) in DMF (50 mL), an appropriate cyclic secondary amine namely, piperidine or morpholine(0.01 mol) was added. The reaction mixture was refluxed for 10-14 h. After completion of the reaction, the reaction mixture was poured onto crushedice with stirring. The formed precipitate was filtered, dried and crystallized from petroleum ether(80-100C) to give the corresponding compounds., 108229-82-9

The synthetic route of 108229-82-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Abbas, Hebat-Allah S.; Al-Marhabi, Aisha R. M.; Ammar, Yousry A.; Acta poloniae pharmaceutica; vol. 74; 2; (2017); p. 445 – 458;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

6298-37-9, Quinoxalin-6-amine is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

6298-37-9, Preparation 6-amino-5-bromoquinoxaline Hydrobromide 6-Aminoquinoxaline (2.08 g, 14.4 mmol) was dissolved in 11.5 ml glacial acetic acid. The solution was cooled in water while a solution of bromine (0.74 ml, 2.3 g, 14.4 mmol) in 1.5 ml glacial acetic acid was added slowly over 15 minutes. After stirring for an additional 30 minutes, the orange red solid formed was filtered off and washed thoroughly with dry ether. The solid was dried in vacuo overnight to yield 4.44 g crude product (a yield of 100%). The compound, 6-amino-5-bromoquinoxaline hydrobromide, had no definite melting point. A phase change from fine powder to red crystals was observed at about 2200 C. Decomposition was observed at about 2450 C. The material was used directly for preparation of 6-amino-5-bromoquinoxaline as follows.

The synthetic route of 6298-37-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Gil, Daniel W.; Whitcup, Scott; Brin, Mitchell F.; Donello, John E.; US2004/266776; (2004); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.,50998-17-9

EXAMPLE 1; 6-[3-(Piperidin-l-ylmethvDphenyllquinoxalineA mixture of 6-bromoquinoxaline (42 mg, 0.2 mmol), 3-(piperidin-l-ylmethyl)- phenylboronic acid pinacol ester hydrochloride (67 mg, 0.21 mmol), 2M aqueous sodium carbonate solution (0.3 mL, 0.6 mmol) and Pd(PPh3 )4 (7 mg, 0.006 mmol) in DME (0.6 mL) was heated to 12O0C in a sealed tube, under microwave irradiation, for 20 minutes. After cooling, the mixture was partitioned between saturated ammonium chloride solution and EtOAc (2 mL each), and the organic phase concentrated in vacuo. The residue was purified by preparative HPLC to give the title compound (34 mg, 56%) as a pale yellow- brown gum. deltaH (CDCl3) 8.88 (d, IH), 8.85 (d, IH), 8.33 (d, IH), 8.19 (d, IH), 8.08 (dd, IH), 7.75 (s, IH), 7.68 (d, IH), 7.48 (t, IH), 7.41 (d, IH), 3.69 (s, 2H), 2.46-2.63 (m, 4H), 1.59-1.72 (m, 4H), 1.40-1.53 (m, 2H). LCMS (ES+) 304 (M+H)+, RT 2.49 minutes.

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Patent; UCB PHARMA S.A.; BUeRLI, Roland; HAUGHAN, Alan, Findlay; MACK, Stephen, Robert; PERRY, Benjamin, Garfield; RAPHY, Gilles; SAVILLE-STONES, Elizabeth, Anne; WO2010/52448; (2010); A2;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider